News Positive phase 3 results for Zealand Pharma's glepaglutide Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the
News MSD adds new indication for Welireg in rare tumours MSD's oral HIF-2 alpha inhibitor Welireg has a third FDA approval, becoming the first oral treatment for a rare solid tumour PPGL or 'pheo para'.
Market Access Sponsored Bridging research and clinical guidelines – interactive stra... Medical affairs is evolving. Understanding how to harness real-world data and digital insights is essential.
